{"filings":[{"id":1508036,"accession_number":"0001628280-26-047584","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2026-07-08T11:03:56+00:00","items":["5.02"],"status":"ready","headline":"Ovid Therapeutics appoints Charles Carter as CFO, replacing Jeffrey Rona","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Jeffrey Rona departed July 6, 2026; no disagreement with company on accounting or financial reporting.","Charles Carter appointed CFO, SVP of Finance since Oct 2024; previously CFO at CERo Therapeutics and iCAD.","Carter receives $460k base salary, 35% target bonus, 50,000 RSUs vesting over 2 years, plus $75k bonus opportunity.","Rona receives 12 months base salary severance, prorated 2026 bonus, COBRA for 12 months, and consulting role through Dec 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":983036,"accession_number":"0001628280-26-042396","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2026-06-11T13:03:18+00:00","items":["5.07"],"status":"ready","headline":"Ovid Therapeutics stockholders elect Jeremy Levin as director, approve advisory say-on-pay and ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jeremy M. Levin elected as director with 87,219,707 for, 8,528,008 withheld.","Advisory say-on-pay approved: 84,511,953 for, 8,901,691 against, 2,334,071 abstain.","Ratification of KPMG as independent auditor for FY2026 approved: 130,845,667 for, 32,505 against, 80,756 abstain.","Quorum achieved with 130,958,928 shares present (75.7% of outstanding)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":815398,"accession_number":"0001628280-26-040038","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2026-06-03T11:03:09+00:00","items":["5.02"],"status":"ready","headline":"Ovid Therapeutics appoints Dr. Anna Greka to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased to seven directors, effective June 15, 2026, with appointment of Anna Greka, M.D., Ph.D. as Class III director.","Dr. Greka is Professor of Medicine at Harvard Medical School and Mass General Brigham, and holds leadership roles at Broad Institute.","She will serve on Compensation Committee and Science and Technology Committee, receiving standard non-employee director compensation.","Standard indemnification agreement entered; no related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":22241,"accession_number":"0001628280-26-033859","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2026-05-12T11:04:29+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Q1 net loss $17M; raises $60M PIPE; dosed first OV4071 Phase 1; OV329 Phase 2 planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net loss of $17.0M ($0.12/share) vs $10.2M loss ($0.14) in Q1 2025.","Cash $165.6M as of Mar 31, 2026; plus $27.3M in April from warrant exercises; runway into 2029.","Dosed first healthy volunteer in Phase 1 study of OV4071, oral KCC2 direct activator, for psychosis.","OV329 shows favorable safety/PK up to 9 mg; Phase 2 for focal onset seizures and TSC/infantile spasms planned.","Raised $60.0M gross from March 2026 PIPE and $53.9M from Series A warrant exercises (Oct 2025 PIPE)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94281,"accession_number":"0001628280-26-025926","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ovid Therapeutics receives $53.9M from exercise of Series A warrants; issues 33.6M common shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Series A warrants from Oct 2025 private placement expired on April 17, 2026; 38,481,325 underlying shares.","Investors exercised 33,597,860 shares at $1.40 each and 4,883,464 pre-funded warrants at $1.399 each.","Gross proceeds of approximately $53.9 million to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106513,"accession_number":"0001628280-26-019045","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2026-03-18T23:59:59+00:00","items":["1.01","2.02","3.02","9.01"],"status":"ready","headline":"Ovid Therapeutics raises $60M PIPE, reports positive OV329 data, expands indications, and clears OV4071 for Phase 1","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$60M PIPE: 19.15M shares at $2.01 and pre-funded warrants for 10.7M shares; closing expected March 19, 2026.","OV329 7 mg cohort: no treatment-related adverse events; Phase 2 for focal onset seizures planned for Q2 2026.","OV329 development expanded to tuberous sclerosis complex seizures (Q4 2026) and infantile spasms (2027).","OV4071 (oral KCC2 activator) received HREC/TGA approval; Phase 1 in Australia starts Q2 2026.","Cash $90.4M at Dec 31, 2025; net loss FY2025 $17.4M ($0.23/share); Series A warrants could add $53.9M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122858,"accession_number":"0001193125-25-323798","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ovid reports Phase 1 safety and PK for OV350; oral KCC2 activator OV4071 on track for Q1 2026 filing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OV350 IV showed good safety; no treatment-related SAEs or lab findings in 16 healthy participants.","PK as predicted; exploratory qEEG indicated central activity consistent with KCC2 modulation.","OV4071 (oral) is 20-fold more potent; regulatory submission for Phase 1/1b expected Q1 2026, clinical start Q2 2026.","Company will not advance OV350 IV further; resources directed to oral KCC2 activators OV4071 and OV4041.","Most common AE was headache; nausea/vomiting in subset attributed to off-target pharmacology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122857,"accession_number":"0001636651-25-000017","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ovid Therapeutics stockholders approve 3 proposals at special meeting including authorized share increase to 315M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved amendment to increase authorized common shares from 125M to 315M: 34.2M for, 1.5M against, 2.4M abstain.","Approved issuance of shares upon conversion of Series B Preferred and exercise of Series A/B Warrants: 34.3M for, 1.3M against, 2.5M abstain.","Approved issuance of securities to CEO Jeremy Levin under Oct 2, 2025 Securities Purchase Agreement: 34.3M for, 1.2M against, 2.5M abstain.","Special meeting held Dec 11, 2025; quorum 38.0M of 71.2M outstanding shares (53.42%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122856,"accession_number":"0001636651-25-000011","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Ovid Therapeutics announces CEO succession, Q3 2025 loss, and pipeline progress","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Meg Alexander appointed CEO effective Jan 1, 2026; Jeremy Levin to become Executive Chairman.","Q3 2025 net loss $12.2M ($0.17/sh) vs $14.0M ($0.20) YoY; cash $25.6M at Sep 30.","Completed $81M private placement (up to $175M); cash runway extended into 2H 2028.","OV329 Phase 1 positive; Phase 2a in drug-resistant epilepsies planned Q2 2026.","OV350 IV data expected Q4 2025; OV4071 oral KCC2 activator to enter clinic Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122855,"accession_number":"0001193125-25-230409","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","3.02","5.03","8.01","9.01"],"status":"ready","headline":"Ovid reports positive Phase 1 OV329 results and raises $175M in PIPE financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["OV329 Phase 1: 53% inhibition increase on LICI biomarker (p=0.0001) at 5mg, exceeding vigabatrin (~35%); mild AEs only.","No ophthalmic changes observed; plan Phase 2a in drug-resistant focal onset seizures Q2 2026.","PIPE financing of up to $175.1M (initial $80.8M) from sale of Series B Preferred and warrants at $1.40/share.","Warrants exercisable after stockholder approval; proceeds for R&D and working capital; closing Oct 6, 2025.","KCC2 program updates: OV350 topline PK data Q4 2025; OV4071 IND filing Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139558,"accession_number":"0001193125-25-204308","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ovid Therapeutics regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received formal notice from Nasdaq on Sept 11, 2025, confirming compliance with Listing Rule 5550(a)(2).","Minimum bid price had been below $1.00; company now meets the requirement.","Nasdaq has closed the matter; no further action needed regarding listing status.","Stock trading symbol OVID remains on The Nasdaq Stock Market LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139557,"accession_number":"0001628280-25-040007","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"Ovid Therapeutics Q2 net loss $4.7M, cash $38.3M; receives Nasdaq extension to Feb 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss of $4.7M ($0.06 EPS) vs net income of $8.5M ($0.12 EPS) in Q2 2024.","Revenue from royalty agreements $6.3M (vs $169K), including $7.0M ganaxolone royalty monetization with Immedica.","Cash $38.3M, expected to fund operations into early 2H 2026.","OV329 Phase 1 topline safety/biomarker results anticipated Q3 2025.","Company transferred to Nasdaq Capital Market with extended bid price compliance deadline to Feb 9, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139556,"accession_number":"0001628280-25-034733","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-07-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ovid Therapeutics shareholders approve reverse stock split authorization at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Kevin Fitzgerald and Bart Friedman to three-year terms with >35M votes for each.","Advisory say-on-pay approved, 35.4M for vs 0.9M against (95% of votes cast).","Ratified KPMG as independent auditor for FY2025, 50.8M for vs 0.2M against.","Authorized board to implement reverse stock split at ratio 1:10 to 1:40, at board's discretion (44.2M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157131,"accession_number":"0001628280-25-032959","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ovid sells future ganaxolone royalties to Immedica for $7.0M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Immedica pays $7.0M to acquire 100% of Ovid's royalty rights on ganaxolone sales outside China.","Ovid recorded ~$566K in ganaxolone royalty revenue in 2024; deal provides non-dilutive funding.","Immedica also obtains additional ganaxolone IP rights and assumes future IP costs.","Transaction expands Immedica's control of ganaxolone; no impact on Ovid's pipeline.","Amended license expected within six months to broaden field and territory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157130,"accession_number":"0001628280-25-024911","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics Q1 net loss $10.2M; OV329 data on track for Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $43.0M at March 31, 2025; expected to fund operations into 2H 2026.","Topline Phase 1 biomarker and safety data for OV329 (GABA-AT inhibitor) expected in Q3 2025.","OV350 KCC2 direct activator dosed in Phase 1 in Q1 2025; safety/tolerability results expected Q4 2025.","Q1 net loss $10.2M ($0.14/sh) vs $11.7M ($0.17/sh) a year ago; total op expenses down 28% to $12.7M.","Oral KCC2 candidate OV4071 on track to initiate proof-of-concept study in H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":223600000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157129,"accession_number":"0001193125-25-111633","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.08"],"status":"ready","headline":"Ovid Therapeutics sets 2025 Annual Meeting for July 9; shareholder proposal deadline May 12","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual Meeting scheduled for July 9, 2025; record date for voting is May 19, 2025.","Shareholder proposals under Rule 14a-8 must be received by May 12, 2025.","Director nominations and other proposals under bylaws also due by May 12, 2025.","Meeting delayed more than 30 days from 2024 anniversary, triggering this 8-K notice.","Stockholders intending to use universal proxy rules must provide Rule 14a-19 notice by May 12, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175491,"accession_number":"0001628280-25-011839","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics Q4/FY2024 net loss $26.4M; cash into H2 2026; OV329 data Q3 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $26.4M ($0.37/diluted) for FY2024 vs $52.3M in 2023; royalty revenue $566K.","Cash & securities $53.1M expected to fund operations into H2 2026.","Topline Phase 1 results for OV329 (GABA-AT inhibitor) expected Q3 2025; no SAEs to date.","OV350 (first KCC2 direct activator) began Phase 1 in Q1 2025; topline data expected Q4 2025.","Stelios Papadopoulos appointed to Board; Manal Morsy (Chief Regulatory Officer) and Victoria Fort (Corporate Affairs) joined."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175490,"accession_number":"0001193125-25-047174","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ovid Therapeutics appoints Stelios Papadopoulos to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from five to six directors; Papadopoulos appointed Class I director, term through 2027 annual meeting.","Papadopoulos co-founded Exelixis, served as Chairman of Biogen (2014-2023), and has extensive biotech investment banking background.","Appointed to Audit Committee and Compensation Committee, effective March 1, 2025.","Non-employee director compensation updated: $45,000 base retainer, initial 90,000 stock options grant, annual 45,000 options.","Entered standard indemnification agreement covering expenses for actions arising from director service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175489,"accession_number":"0001193125-25-026192","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Ovid Therapeutics receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq notice on Feb 10, 2025, that average closing bid price was below $1.00 for 31 consecutive trading days.","Company has 180 days, until Aug 11, 2025, to regain compliance by closing at $1.00 for 10 consecutive business days.","No immediate impact on listing; common stock continues to trade on Nasdaq while options to cure are explored.","If not cured by Aug 11, Ovid may seek a second 180-day period by transferring to Nasdaq Capital Market.","Failure to cure could lead to delisting, with appeal rights to a Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192444,"accession_number":"0001628280-24-046867","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Q3 net loss $14.0M ($0.20/share); cash $62.7M; pauses CCM Phase 2, advances OV329/OV350","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.0M ($0.20 per share) vs $11.3M in Q3 2023; royalty revenue $173K.","Cash and marketable securities $62.7M; expected to fund operations into H2 2026.","Phase 1 MAD study of OV329 progressing; plans to add cohorts for higher dosing; topline data in 2025.","Regulatory application for Phase 1 trial of OV350 (KCC2 direct activator) expected in Q4 2024; first-in-human Q1 2025.","Pause of Phase 2 study of OV888/GV101 in CCM to incorporate competitor trial insights; ROCK2 programs continue."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":223400000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208915,"accession_number":"0001193125-24-217302","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Ovid Therapeutics appoints Meg Alexander as President and COO effective Sept 9","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Annual base salary of $500,000; target bonus of 45% of base salary.","Granted option to purchase 140,000 shares at $1.07 per share, 10-year term.","Option vests 25% on one-year anniversary, then monthly over 36 months.","Severance includes 12 months salary and COBRA gross-up on covered termination.","Alexander previously served as Chief Strategy Officer since June 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208914,"accession_number":"0001628280-24-036859","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics cuts workforce 43%, suspends OV329 IV, reports Q2 net income of $8.5M on $77M cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reduced headcount by 17 employees (43%) to prioritize core programs; expects $3.4M cash restructuring costs through mid-2025.","Suspended OV329 IV program for refractory status epilepticus; oral OV329 Phase 1 MAD results due H2 2024.","Appointed Dr. Amanda Banks as Chief Development Officer in July 2024.","Q2 2024 net income of $8.5M ($0.12 EPS) vs net loss of $12.4M ($0.18 loss) in 2023, aided by $29M fair value gain on royalty liability.","Cash and marketable securities of $77.0M expected to fund operations and 5 clinical/regulatory milestones through late H1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":223200000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208913,"accession_number":"0001628280-24-034481","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-08-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ovid Therapeutics enters consulting agreement with departing General Counsel Thomas Perone","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas Perone departed as General Counsel, CCO and Corporate Secretary effective July 11, 2024, as part of a workforce reduction.","Consulting agreement effective July 11, 2024 through January 31, 2025 to transition duties.","Perone eligible for monthly consulting fee totaling up to $55,000 over the consulting period.","Outstanding equity awards will continue to vest during the consulting period.","Consulting agreement includes post-termination non-solicitation covenants through one year after termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208912,"accession_number":"0001628280-24-030546","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ovid/Graviton announce positive Phase 1 data for OV888/GV101 CCM therapy; Phase 2 expected H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 met primary safety/tolerability objectives: no serious adverse events at any dose.","Headache was most common AE (23%); all mild and resolved within 24 hours.","Target PK achieved: half-life ~12 hours supports once-daily dosing.","Dose-dependent decrease in proinflammatory cytokines IL-17 and IL-21 confirms ROCK2 target engagement.","Phase 2 proof-of-concept study in cerebral cavernous malformations planned for second half 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226724,"accession_number":"0001193125-24-172225","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["2.05","5.02","7.01"],"status":"ready","headline":"Ovid Therapeutics cuts workforce by 43%, two executives depart","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduced by 17 employees (~43% of headcount); one-time severance charge of ~$4.0M; substantially complete by Q3 2024.","General Counsel Thomas Perone and COO Jason Tardio depart effective July 11, 2024; consulting transition arrangements planned.","Cash runway extended into first half of 2026 due to cost savings from workforce reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226723,"accession_number":"0000950170-24-073998","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ovid reports Takeda's Ph3 soticlestat misses primary endpoints; pipeline and cash runway update","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Takeda's Phase 3 SKYLINE in Dravet syndrome narrowly missed primary endpoint (p=0.06) but showed significant secondary endpoints (p≤0.008).","Takeda's Phase 3 SKYWAY in Lennox-Gastaut syndrome missed primary endpoint; safety profile consistent.","Ovid's cash runway expected into H1 2026; pipeline milestones include OV888 Phase 2 start H2 2024, OV329 data H2 2024, OV350 IND H2 2024.","Takeda will discuss data with regulators; Ovid will update guidance on potential milestones/royalties afterward."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226722,"accession_number":"0000950170-24-070673","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ovid Therapeutics stockholders elect directors, approve executive compensation, ratify KPMG","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Proposal 1: Barbara Duncan and Robert Michael Poole elected to board; For votes 36.7M and 40.2M respectively.","Proposal 2: Advisory vote on executive compensation approved with 40.5M For, 1.76M Against, 0.01M Abstain.","Proposal 3: Ratification of KPMG as auditor for FY2024 passed with 57.2M For, 1.29M Against, 9,375 Abstain.","Broker non-votes totaled 16.2M shares on Proposals 1 and 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226721,"accession_number":"0001628280-24-023064","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics reports Q1 2024 net loss of $11.7M; cash $90.3M; Takeda Phase 3 soticlestat data expected by Sep 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $11.7M ($0.17/share) vs $13.4M ($0.19) in Q1 2023; revenue $148K.","Cash $90.3M as of Mar 31, 2024; expected to fund operations into H1 2026.","Takeda completed Phase 3 trials for soticlestat in LGS and Dravet; topline data expected in H1 2024 fiscal year (by Sep 2024).","OV888 (GV101) Phase 1 MAD complete; no serious AEs; Phase 2 in CCM expected H2 2024.","Ovid retains 87% interest in soticlestat milestones (up to $660M) and tiered royalties up to 20%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245679,"accession_number":"0001628280-24-009807","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics reports Q4 2023 financial results and pipeline updates; soticlestat Phase 3 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet syndromes completed enrollment; Takeda expects topline data by September 2024.","Cash and marketable securities of $105.8M as of Dec 31, 2023; expected runway into first half of 2026.","OV888 (GV101) Phase 1 multiple-ascending dose study progressing; no serious adverse events; higher dose cohort added.","Net loss of $52.3M for full year 2023 compared to $54.2M in 2022; basic net loss per share $0.74.","Ovid retains 87% interest in soticlestat milestones and royalties; potential payments up to $660M plus low double-digit royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263152,"accession_number":"0000950170-23-068591","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Ovid Therapeutics CEO gifts 1.15M shares to family trusts for estate planning","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Jeremy Levin gifted 1,146,500 shares of Ovid common stock to family trusts for his two daughters.","After gift, Dr. Levin holds 3,598,467 shares of outstanding common stock.","Transfers made for no consideration as part of year-end estate tax planning.","Form 4 filed with SEC on December 6, 2023 reporting the gifts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263151,"accession_number":"0001628280-23-036563","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics Q3 net loss $11.3M; secures $30M from Ligand for soticlestat royalty interest","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Received $30M from Ligand for 13% interest in soticlestat future royalties/milestones; cash runway extended into 2026.","Cash and equivalents $87.1M as of Sep 30, 2023, excluding the $30M received in Oct.","Net loss $11.3M ($0.16 per share) vs $12.0M ($0.17) in Q3 2022.","Takeda anticipates regulatory filings for soticlestat in fiscal year 2024; two Phase 3 trials on track.","OV329 expanding to IV formulation; IND expected H2 2024. OV350 (KCC2) IND also expected H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":222800000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263150,"accession_number":"0000950170-23-053875","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Ovid sells 13% of soticlestat royalties & milestones to Ligand for $30M; cash runway into 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ligand pays Ovid $30M (non-dilutive) for 13% of soticlestat regulatory/commercial milestones and tiered royalties (low double-digits to 20%).","Ovid retains 87% of soticlestat economic interest; Takeda funds all development and has no further obligations for Ovid.","Cash runway extended into 2026 (from into 2025), enabling expansion of pipeline of rare epilepsy and anti-seizure programs.","Soticlestat is in two pivotal Phase 3 trials for Lennox-Gastaut and Dravet syndromes; Takeda anticipates regulatory filings in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263149,"accession_number":"0000950170-23-050995","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ovid Therapeutics posts R&D Day corporate presentation; no financial or clinical updates","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Presentation posted Oct 2, 2023, on Ovid investor relations website.","Slide titled 'Dawn of the neurotherapeutics era' by CEO Dr. Jeremy Levin.","Filing exhibit includes only the cover slide; no detailed data disclosed.","No material news regarding pipeline, financials, or guidance in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280362,"accession_number":"0001628280-23-027426","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics Q2 net loss $12.4M; OV329 SAD complete; Graviton ROCK2 collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $96.5M as of June 30, 2023; net loss $0.18 per share vs $0.21 year ago.","OV329 Phase 1 single-ascending-dose portion completed with no safety signals; full data expected H1 2024.","Entered license/collaboration with Graviton for ROCK2 inhibitors with $10M equity investment.","Appointed Dr. Zhong Zhong CSO and Dr. Manoj Malhotra CMO; Meg Alexander promoted to Chief Strategy Officer.","Implemented cost-cutting measures including G&A headcount reduction; cash runway expected into 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":222600000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298894,"accession_number":"0000950170-23-027151","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ovid Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Karen Bernstein re-elected with 39.7M for, 5.1M withheld; Jeremy Levin re-elected with 44.5M for, 0.4M withheld (16.5M broker non-votes).","Say-on-pay approved: 44.7M for, 113,666 against, 40,903 abstain (16.5M broker non-votes).","Shareholders recommended one-year frequency for say-on-pay (44.0M for one year, 793,928 for three years).","Ratification of KPMG as auditor for FY2023: 61.2M for, 65,728 against, 2,922 abstain.","Board determined future say-on-pay votes will be annual until at least 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298893,"accession_number":"0001628280-23-015996","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Q1 net loss $13.4M; cash $117.7M; adds ROCK2 program via Graviton","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.4M ($0.19 loss per share) vs $16.1M ($0.23) in Q1 2022; operating expenses $15.0M.","Cash, equivalents and marketable securities $117.7M as of March 31; expected runway into 2025.","Collaboration with Graviton adds GV101 (ROCK2 inhibitor); Phase 2 for brainstem cavernous malformations targeted for 2024.","OV329 Phase 1 on track with no safety signals; full data expected H1 2024; OV350 advancing preclinically.","Concluding Columbia University genetic collaboration by year-end; out-licensing options explored."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":222600000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298892,"accession_number":"0000950170-23-016250","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-05-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Ovid Therapeutics enters ROCK2 inhibitor collaboration with Graviton; invests $10M for exclusive CNS rights","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Ovid pays $10M upfront in Graviton Series A preferred stock for exclusive license to GV101 and other ROCK2 inhibitors.","Royalties on net sales range from mid-teens to high-teens; no milestone payments are required.","Initial focus: cerebral cavernous malformations and seizure disorders; GV101 is in Phase 1.","Graviton conducts development through Phase 2; Ovid handles post-Phase 2 development and commercialization worldwide except China, Hong Kong, Macau, Taiwan.","Ovid CEO Dr. Jeremy Levin will join Graviton's Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":298891,"accession_number":"0000950170-23-015343","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Soticlestat long-term OLE data shows sustained seizure reduction in Dravet and LGS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ENDYMION 1 interim analysis: soticlestat generally safe and well tolerated over ~2 years; 78% tolerated 300 mg BID.","Dravet patients: median convulsive seizure reduction -33.7% (wk1-12), -47.8% (wk49-60), -58.2% (wk97-108).","LGS patients: median drop seizure reduction -29.3% (wk1-12), -14.1% (wk49-60), -36.6% (wk97-108).","Post-hoc ELEKTRA analysis: soticlestat showed numerically superior reduction vs placebo across most seizure types.","Ovid maintains significant financial interest in soticlestat (milestones and royalties from Takeda)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319077,"accession_number":"0001628280-23-007636","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics reports FY2022 net loss $54.2M; cash $129M; pipeline advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2022 $54.2M ($0.77 per share) vs net income $122.8M ($1.78) in 2021, driven by prior Takeda milestone.","Cash and equivalents $129.0M; expected to fund operations into first half of 2025.","OV329 Phase 1 trial on track; full data with biomarker efficacy proxy expected H1 2024.","Takeda reaffirms soticlestat regulatory filings in FY2024; Ovid eligible for up to $660M milestones plus royalties.","Added epileptologist Manoj Malhotra and co-inventor Toshiya Nishi to leadership in Q1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319076,"accession_number":"0001628280-23-007568","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Ovid Therapeutics confirms no exposure to Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company holds no deposits or securities at Silicon Valley Bank.","No accounts maintained at SVB as of March 10, 2023.","Filing addresses investor concerns amid SVB collapse.","Ovid's cash and investments are held in other institutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337303,"accession_number":"0001628280-22-028771","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics Q3 2022 net loss $12.0M; $137.9M cash; OV329 Phase 1 to start Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.0M ($0.17 per share) vs $11.4M loss in Q3 2021; R&D expense $5.2M.","Cash, cash equivalents and marketable securities totaled $137.9M as of Sept 30, 2022.","FDA cleared IND for OV329; Phase 1 trial in healthy volunteers planned for Q4 2022.","Executed additional $3.5M investment in Gensaic convertible preferred stock for gene delivery platform.","Takeda continues pivotal Phase 3 trials for soticlestat; Ovid eligible for up to $660M milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":1456468.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":354670,"accession_number":"0001628280-22-021758","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics Q2 2022 net loss $14.6M; cash $152.4M; OV329 IND on track for H2 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $14.6M ($0.21 per share) vs $15.8M loss ($0.23) in Q2 2021.","Cash, equivalents & marketable securities $152.4M, expected to fund pipeline into 2025.","R&D expenses $6.0M (down from $7.7M) due to discontinuation of OV101 study and Takeda termination.","OV329 IND submission and Phase 1 start planned for H2 2022; preclinical data shown at epilepsy meetings.","KCC2 activator IND expected in 2024; Takeda reiterates soticlestat regulatory filing in FY2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":1445366.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372673,"accession_number":"0000950170-22-011472","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Ovid Therapeutics annual meeting elects two directors, ratifies KPMG","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting held June 9, 2022; 58.53% quorum (41,220,715 of 70,417,345 shares).","Kevin Fitzgerald elected: 23,339,939 for, 76,303 withheld; broker non-votes 17,804,473.","Bart Friedman elected: 17,204,205 for, 6,212,037 withheld; broker non-votes 17,804,473.","Ratification of KPMG as auditor for FY2022: 40,049,679 for, 1,157,936 against, 13,100 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372672,"accession_number":"0000950170-22-009147","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Takeda notifies Ovid of soticlestat Phase 3 delays; primary completion March 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Takeda notified Ovid that two pivotal Phase 3 soticlestat trials (Dravet & Lennox-Gastaut) are likely delayed due to Ukraine/Russia and China COVID lockdowns.","Primary completion date now estimated March 2024; regulatory filings expected in Takeda's fiscal 2024.","Takeda stated studies remain highest-priority late-stage programs; actively recruiting with multiple approaches to minimize delays.","Ovid retains significant financial interest in soticlestat's development and potential commercialization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":372671,"accession_number":"0000950170-22-008734","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2022-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid reports Q1 net loss $16.1M, revenue $1.4M; OV329 IND on track for Q4 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $16.1M ($0.23/sh) vs net income $176M in Q1 2021 on one-time Takeda payment.","Revenue fell to $1.4M from $208.4M; current revenue from Marinus and Healx license fees.","Cash and equivalents $166.7M expected to fund pipeline into 2025.","IND for OV329 (GABA aminotransferase inhibitor) planned in Q4 2022 to start Phase 1.","Non-GAAP adjusted operating expenses were $14.2M; total operating expenses $17.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":1445366.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391495,"accession_number":"0000950170-22-003665","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2022-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Ovid Therapeutics reduces workforce 20%, extends cash runway beyond 2024; OV329 on track for 2022 clinical entry","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Workforce reduced by ~20% to extend cash runway beyond 2024 as part of organizational restructuring.","OV329, a GABA aminotransferase inhibitor, expected to enter clinical trials in 2022 for tuberous sclerosis seizures.","Takeda to present pivotal Phase 3 soticlestat results in Dravet and Lennox-Gastaut syndromes in 2023.","Financial results for Q4/FY2021 reported but specific figures not provided in filing excerpt; focus on cost reduction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":391494,"accession_number":"0001564590-22-000016","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2022-01-03T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Ovid licenses KCC2 activator library from AstraZeneca; $5M cash + $7.5M stock upfront","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exclusive worldwide license for early-stage small molecules targeting KCC2, including lead OV350.","Upfront consideration: $5M cash + $7.5M in Ovid common stock (2,272,727 shares).","Milestones up to $8M clinical, $45M regulatory, $150M commercial; royalties single-digit to 10%.","AstraZeneca retains right of first negotiation at proof of clinical efficacy for strategic collaboration.","OV350 shows in-vitro/in-vivo proof of concept in resistant epilepsy; Ovid to collaborate with Drs. Moss, Maguire."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409699,"accession_number":"0001193125-21-325375","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2021-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Ovid Therapeutics reports Q3 2021 net loss of $11.4M, cash $201.8M, and business development strategy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $201.8M as of Sept 30, 2021; net loss $11.4M ($0.17 per share) vs $16.4M ($0.28) in Q3 2020.","Revenue zero vs $6.9M in Q3 2020; R&D expenses down to $4.9M from $15.9M due to OV101 wind-down and soticlestat termination.","Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet enrolling; Ovid eligible for up to 20% royalties on global sales.","Ovid plans to pursue business development for precision therapeutics; targets IND submission for OV329 in 2022.","Kevin Fitzgerald, Ph.D., former Alnylam CSO, appointed to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":2.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":221000000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":409698,"accession_number":"0001564590-21-050376","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2021-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ovid Therapeutics appoints Dr. Kevin Fitzgerald as director, grants stock options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Dr. Kevin Fitzgerald, Ph.D. to Board as Class II director effective Oct 6, 2021.","Initial option for 30,000 shares at $3.44 exercise price, vesting monthly over 3 years.","Annual cash compensation of $40,000 prorated; eligible for 15,000-share annual option grant.","No arrangements or understandings with any other person regarding appointment; no family relationships.","Standard indemnity agreement entered; compensation per Non-Employee Director Compensation Policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":428602,"accession_number":"0001564590-21-044971","cik":1636651,"company_name":"Ovid Therapeutics Inc.","ticker":"OVID","form_type":"8-K","filed_at":"2021-08-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Ovid posts August 2021 corporate overview; no specific financial or operational updates provided in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company posted corporate presentation to website but full content not included in filing text.","No new financial guidance, clinical trial results, or business developments disclosed.","Presentation likely covers pipeline, strategy, and forward-looking statements.","Filing is a routine disclosure of a corporate overview; no specific numbers available."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":474999063.51771647,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-08-18T23:59:59+00:00|428602"}